The estimated Net Worth of Arye Weigensberg is at least $142 Tisíc dollars as of 25 May 2024. Mr Weigensberg owns over 3,972 units of Cronos Inc stock worth over $142,129 and over the last 2 years he sold CRON stock worth over $0.
Mr has made over 6 trades of the Cronos Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,972 units of CRON stock worth $8,659 on 25 May 2024.
The largest trade he's ever made was exercising 24,237 units of Cronos Inc stock on 15 March 2024 worth over $52,837. On average, Mr trades about 6,632 units every 58 days since 2022. As of 25 May 2024 he still owns at least 65,197 units of Cronos Inc stock.
You can see the complete history of Mr Weigensberg stock trades at the bottom of the page.
Arye Weigensberg is the Interim Head of R&D at Cronos Inc.
Arye's mailing address filed with the SEC is 111 PETER STREET, SUITE 300, , TORONTO, A6, M5V 2H1.
Over the last 4 years, insiders at Cronos Inc have traded over $30,495,757 worth of Cronos Inc stock and bought 1,848,320 units worth $4,899,192 . The most active insiders traders include Michael Ryan Gorenstein, Jason Marc Adler a Jeffrey David Jacobson. On average, Cronos Inc executives and independent directors trade stock every 15 days with the average trade being worth of $528,456. The most recent stock trade was executed by James Andrew Iii Mc Ginness on 29 August 2024, trading 14,618 units of CRON stock currently worth $31,867.
cronos group is a globally diversified and vertically integrated cannabis company with a presence across four continents. the company operates two wholly-owned canadian licensed producers regulated under health canada’s access to cannabis for medical purposes regulations: peace naturals project inc. (ontario), which was the first non-incumbent medical cannabis license granted by health canada, and original bc ltd. (british columbia), which is based in the okanagan valley. the company has multiple international production and distribution platforms: cronos israel and cronos australia. through an exclusive distribution agreement, cronos also has access to over 12,000 pharmacies in germany as the company focuses on building an international iconic brand portfolio and developing disruptive intellectual property.
Cronos Inc executives and other stock owners filed with the SEC include: